Cancer Highlights
A decision support tool to optimize your cancer pipeline portfolio. From research and development to Market. Cancer Highlights™ is BioSeeker Group’s flagship decision support tool, for portfolio assessment and planning of cancer drug development. Cancer Highlights™ uses standardized criteria in a five pillar assessment to compare drug development strategies in oncology, making it easy to find and compare analysis not only within one single Cancer Focus Area but also between different areas.
-
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
€2,450.00Published by BioSeeker Group on Jan 30th, 2012This report comprises defined and up to date development strategies for 252 angiogenesis affecting drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications. Learn More -
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
€2,450.00Published by BioSeeker Group on Dec 19th, 2011This report will excel your competitive awareness and decrease your decision making time in managing apoptotic drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you. Learn More -
Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others
€2,450.00Published by BioSeeker Group on Nov 14th, 2011This report will excel your competitive awareness and decrease your decision making time in managing peptide drug development in cancer. Learn More -
The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others
€2,450.00Published by BioSeeker Group on Sep 27th, 2011This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely antibodies for the treatment of cancer. Learn More -
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
€1,950.00Published by BioSeeker Group on Jul 12th, 2011This report comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 217 companies, from Ceased to Marketed. The report extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and three subindications of lung cancer. Learn More -
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
€1,950.00Published by BioSeeker Group on May 18th, 2011This report comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 152 companies, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and five subindications of lymphoma. Learn More -
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market
€1,950.00Published by BioSeeker Group on Apr 25th, 2011This report comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 companies, from Ceased to Marketed. The report extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and eight subindications of leukemia. Learn More -
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market
€1,950.00Published by BioSeeker Group on Mar 7th, 2011 -
A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
€1,950.00Published by BioSeeker Group on Nov 17th, 2010This report comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 companies, from Ceased to Marketed. The report extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma. Learn More -
Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
€1,950.00Published by BioSeeker Group on Oct 14th, 2010This report comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. The report extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications. Learn More -
Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline
€2,450.00Published by BioSeeker Group on Sep 7th, 2010This report comprises defined and up to date development strategies for 239 angiogenesis affecting drugs in oncology within the portfolio of 148 corporate investigators, from Ceased to Marketed. The report extensively analyses their 174 identified drug targets, organized into 167 drug target strategies, and assesses them in 64 different cancer indications. Learn More -
Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
€2,450.00Published by BioSeeker Group on Jun 24th, 2010This report identifies the competitive terrain for cancer therapeutic peptides to be wide open from a compound perspective and the opportunity for peptide drugs to challenge other biologicals such as antibodies is real and significant. Learn More -
A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market
€1,950.00Published by BioSeeker Group on May 24th, 2010This report comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. The report extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer. Significantly new prostate cancer therapies will soon come to challenge old established drugs on the market. Four out of five target strategies in Phase III and nine out of ten in Phase II are novel and innovative in their design. Learn More -
Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place
€1,950.00Published by BioSeeker Group on Apr 26th, 2010This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. The report extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer. Significantly new breast cancer therapies will soon come to challenge old established drugs on the market. Learn More -
Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?
€1,950.00Published by BioSeeker Group on Mar 23rd, 2010The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in pancreatic cancer. Learn More